NPS Pharmaceuticals (NPSP) 10-Q 6 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 30, 2014
Document And Entity Information	'	'
Entity Registrant Name	'NPS PHARMACEUTICALS INC	'
Entity Central Index Key	'0000890465	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'Yes	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	106,561,506

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$53,307	$51,204
Marketable investment securities	116,175	129,270
Accounts receivable	43,186	41,242
Inventory	32,680	30,035
Prepaid expenses	6,868	5,621
Other current assets	1,579	1,380
Total current assets	253,795	258,752
Property and equipment, net	4,850	4,402
Goodwill	9,429	9,429
Intangibles, net	18,402	19,301
Debt issuance costs, net	284	338
Other	205	0
Total assets	286,965	292,222
Current Liabilities	'	'
Accounts payable and accrued expenses	33,770	33,117
Convertible notes payable	0	16,545
Current portion of non-recourse debt	9,270	8,752
Total current liabilities	43,040	58,414
Non-recourse debt, less current portion	107,477	123,635
Other liabilities	7,443	5,283
Total liabilities	157,960	187,332
Commitments and contingencies (notes 6 and 8)	'	'
Stockholders' equity:	'	'
Preferred stock, $0.001 par value. Authorized 5,000,000 shares; issued and outstanding no shares	0	0
Common stock, $0.001 par value. Authorized 175,000,000 shares; issued and outstanding 106,559,852 shares and 102,613,780 shares, respectively	107	103
Additional paid-in capital	1,156,278	1,127,420
Accumulated other comprehensive income	-107	56
Accumulated deficit	-1,027,273	-1,022,689
Total stockholders' equity	129,005	104,890
Total liabilities and stockholders' equity	$286,965	$292,222

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Stockholders' deficit	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	175,000,000	175,000,000
Common stock, shares issued	106,559,852	102,613,780
Common stock, shares outsatnding	106,559,852	102,613,780

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues:	'	'	'	'
Product sales, net	$21,955	$4,801	$39,826	$5,455
Royalties	34,172	31,704	60,341	56,484
Total revenues	56,127	36,505	100,167	61,939
Cost of sales	2,737	473	4,614	538
Operating expenses:	'	'	'	'
Research and development	21,151	30,888	41,708	46,583
Selling, general and administrative	26,449	14,465	51,003	28,670
Total operating expenses	47,600	45,353	92,711	75,253
Operating income (loss)	5,790	-9,321	2,842	-13,852
Other income (expense)	'	'	'	'
Interest income, net	103	58	224	113
Interest expense	-3,648	-3,034	-7,683	-6,429
Other	10	-88	307	-13
Total other expense, net	-3,535	-3,064	-7,152	-6,329
Income (loss) before income tax expense	2,255	-12,385	-4,310	-20,181
Income tax expense	263	4	274	4
Net income (loss)	$1,992	($12,389)	($4,584)	($20,185)
Net income (loss) per common and potential common share	'	'	'	'
Basic	$0.02	($0.13)	($0.04)	($0.22)
Diluted	$0.02	($0.13)	($0.04)	($0.22)
Weighted average common and potential common shares outstanding	'	'	'	'
Basic	106,807	97,321	105,218	92,886
Diluted	110,503	97,321	105,218	92,886

Condensed_Conslidated_Statemen

Condensed Conslidated Statements of Comprehensive Income (Loss) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net income (loss)	$1,992	($12,389)	($4,584)	($20,185)
Unrealized gains (losses) on securities:	'	'	'	'
Unrealized holding gains (losses) arising during period	35	-82	21	-73
Reclassification for recognized gain (loss) on marketable investment securities during the period	0	-2	7	-2
Net unrealized gain (loss) on marketable investment securities	35	-84	28	-75
Foreign currency translation (loss) gain	-189	7	-191	9
Other comprehensive loss	-154	-77	-163	-66
Comprehensive income (loss)	$1,838	($12,466)	($4,747)	($20,251)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($4,584)	($20,185)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	1,589	1,121
Accretion of premium on marketable investment securities	1,760	1,068
Shares issued for payment of services	0	549
Non-cash interest expense	4,314	5,955
Non-cash royalties	-20,317	-19,784
Compensation expense on share-based awards	7,588	5,062
Realized gain on sale of marketable investment securities	-7	-2
(Increase) decrease in operating assets:	'	'
Accounts receivable	-1,650	-4,108
Inventory	-2,645	6,573
Prepaid expenses, other current assets and other assets	-1,651	460
(Decrease) increase in operating liabilities:	'	'
Accounts payable and accrued expenses	644	6,288
Other liabilities	2,210	-1,159
Net cash used in operating activities	-12,749	-18,162
Cash flows from investing activities:	'	'
Sales of marketable investment securities	3,426	4,501
Maturities of marketable investment securities	74,533	42,156
Purchases of marketable investment securities	-66,589	-74,888
Acquisitions of property and equipment	-1,066	-364
Net cash provided by (used in) investing activities	10,304	-28,595
Cash flows from financing activities:	'	'
Net proceeds from the sale of common stock	0	93,454
Net proceeds from the exercise of stock options	6,612	6,585
Excess tax benefit from stock options	122	0
Shares withheld for the payment of taxes	-1,995	-574
Net cash provided by financing activities	4,739	99,465
Effect of exchange rate changes on cash	-191	9
Net increase in cash and cash equivalents	2,103	52,717
Cash and cash equivalents at beginning of period	51,204	17,471
Cash and cash equivalents at end of period	53,307	70,188
Supplemental Disclosures of Cash Flow Information	'	'
Cash paid for interest	256	472
Cash paid for income taxes	84	0
Supplemental Disclosure of Non-cash Investing and Financing Activities	'	'
6.1 million shares of NPS common stock issued in connection with the Takeda Termination and Transition agreement	0	55,403
Unrealized (loss) gain on marketable investment securities	28	75
Accrued acquisition of property and equipment	500	114
Noncash reductions of debt	15,640	12,667
Conversion of 5.75% convertible notes	$16,535	$0

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Parenthetical)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Statement of Cash Flows [Abstract]	'	'
6.1 million shares of NPS common stock issued	0	6.1
Conversion of 5.75% convertible notes	5.75%	'

Basis_of_Presentation_Note_1

Basis of Presentation - Note 1	6 Months Ended
	Jun. 30, 2014
Basis of Presentation	'
Basis of Presentation	'
	(1) Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements included herein have been prepared by NPS Pharmaceuticals, Inc. (NPS Pharma or the Company) in accordance with the rules and regulations of the United States Securities and Exchange Commission (SEC). The condensed consolidated financial statements are comprised of the financial statements of NPS Pharma and its subsidiaries collectively referred to as the Company. In management's opinion, the interim financial data presented includes all adjustments (consisting solely of normal recurring items) necessary for fair presentation. All intercompany accounts and transactions have been eliminated. Certain information required by U.S. generally accepted accounting principles has been condensed or omitted in accordance with rules and regulations of the SEC. Operating results for the three or six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for any future period or for the year ending December 31, 2014.
	These condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and the notes thereto for the year ended December 31, 2013, included in NPS Pharma's 2013 Annual Report on Form 10-K filed with the SEC.
	The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions relating to reporting of the assets and liabilities and the disclosure of contingent assets and liabilities to prepare these condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period in conformity with U.S. generally accepted accounting principles. Actual results could differ from these estimates.
	Subsequent Events
	The Company has evaluated all events and transactions since June 30, 2014. The Company did not have any material recognized or non-recognized subsequent events.

Income_Loss_Per_Common_Share_N

Income (Loss) Per Common Share - Note 2	6 Months Ended
	Jun. 30, 2014
Income (Loss) Per Common Share	'
	(2) Income (Loss) Per Common Share
	The following table sets forth the components of basic and diluted income per common share for the three months ended June 30, 2014 due to net income in the three month period (in thousands, except per share data):
		Three Months
		Ended
			30-Jun-14
	EPS Numerator — Basic:
	Net income	$	1,992
	EPS Denominator — Basic:
	Weighted-average number of shares of common
	stock outstanding		106,807
	EPS Numerator — Diluted:
	Net income	$	1,992
	EPS Denominator — Diluted:
	Weighted-average number of shares of common
	stock outstanding		106,807
	Effect of dilutive securities:
	Stock options and awards		3,696
	Dilutive potential common shares		3,696
	Weighted-average common shares and dilutive
	potential common shares		110,503
	Basic net income per common share	$	0.02
	Diluted net income per common share	$	0.02
	Basic net income (loss) per common share is the amount of income (loss) for the period divided by the weighted average shares of common stock outstanding during the reporting period. Diluted income (loss) per common share is the amount of income (loss) for the period plus interest expense on convertible debt divided by the sum of weighted average shares of common stock outstanding during the reporting period and weighted average shares that would have been outstanding assuming the issuance of common shares for all dilutive potential common shares.
	Potential common shares of approximately 1.4 million and 6.5 million during the three and six months ended June 30, 2014, respectively and 6.3 million and 8.1 million during the three and six months ended June 30, 2013, respectively, that could potentially dilute basic income per share in the future were not included in the computation of diluted income (loss) per share because to do so would have been anti-dilutive for the periods presented. Potential dilutive common shares related to convertible debt were approximately 267,000 and 1.6 million during the three and six months ended June 30, 2014, respectively, and 3.0 million for the three and six months ended June 30, 2013, respectively. Additionally, potential dilutive common shares related to stock options, restricted stock and restricted stock units were 1.1 million and 4.8 million for the three and six months ended June 30, 2014, respectively, and 3.3 million and 5.1 million for the three and six months ended June 30, 2013, respectively.

Fair_Value_Measurement_Note_3

Fair Value Measurement - Note 3	6 Months Ended
	Jun. 30, 2014
Fair Value Measurement Disclosure	'
Fair Value Measurement	'
	(3) Fair Value Measurement
	The Company's financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows:
	Level 1- Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
	Level 2- Inputs are other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
	Level 3- Inputs are unobservable and reflect the Company's assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.
	Summary of Assets Recorded at Fair Value
	In accordance with the fair value hierarchy described above, the following table shows the fair value of the Company's financial assets (only marketable investment securities) that are required to be measured at fair value as of June 30, 2014 and December 31, 2013 (in thousands):
	As of June 30, 2014:		Level 1			Level 2			Level 3			Total
	Certificate of deposits	$	-		$	13,602		$	-		$	13,602
	Corporate		-			88,615			-			88,615
	Government agencies		-			14,458			-			14,458
	Money market funds		37,903			-			-			37,903
	Total assets at fair value	$	37,903		$	116,675		$	-		$	154,578
	As of December 31, 2013:		Level 1			Level 2			Level 3			Total
	Certificate of deposits	$	-		$	13,020		$	-		$	13,020
	Corporate		-			91,887			-			91,887
	Government agencies		-			27,131			-			27,131
	Money market funds		23,043			-			-			23,043
	Total assets at fair value	$	23,043		$	132,038		$	-		$	155,081
	As of June 30, 2014 and December 31, 2013, the fair values of the Company's Level 2 securities were $116.7 million and $132.0 million, respectively. These securities are certificates of deposit, commercial paper, corporate or government agency debt issued by domestic companies or agencies with an original maturity of less than 18 months. These securities are currently rated A-1 or higher. The Company's cash equivalents are classified within Level 1 or Level 2 of the fair value hierarchy because they are valued using quoted market prices or broker or dealer quotations for similar assets. These investments are initially valued at the transaction price and subsequently valued utilizing third-party pricing providers or other market observable data. Data used in the analysis include reportable trades, broker/dealer quotes, bids and offers, benchmark yields and credit spreads. The Company validates the prices provided by its third-party pricing providers by reviewing their pricing methods, analyzing pricing inputs and confirming that the securities have traded in normally functioning markets. The Company did not adjust or override any fair value measurements provided by its pricing providers as of June 30, 2014 or December 31, 2013.
	As of June 30, 2014 and December 31, 2013, the Company did not have any investments in Level 3 securities.
	There were no transfers of assets or liabilities between Level 1 and Level 2 during the three or six months ended June 30, 2014 and 2013.
	The carrying amounts reflected in the condensed consolidated balance sheets for certain short-term financial instruments including accounts receivable, accounts payable, accrued expenses, and other liabilities approximate fair value due to their short-term nature, except that the estimated fair value and carrying value of a royalty liability to the Brigham and Women's Hospital related to sales of cinacalcet HCl using a discounted cash flow model is approximately $3.5 million and $4.6 million, respectively, at June 30, 2014 and $4.3 million and $5.6 million, respectively, at December 31, 2013.
	Summary of Liabilities Recorded at Carrying Value
	The fair and carrying value of our debt instruments are detailed as follows (in thousands):
					As of June 30, 2014						As of December 31, 2013
					Fair			Carrying			Fair			Carrying
					Value			Value			Value			Value
	5.75% Convertible Notes*			$	-		$	-		$	92,338		$	16,545
	Sensipar Notes				40,550			40,616			54,097			54,395
	rhPTH 1-84-Secured Debt				53,415			42,790			50,058			42,790
	Regpara-Secured Debt				36,376			33,341			37,348			35,202
	Total			$	130,341		$	116,747		$	233,841		$	148,932
	* See Note 6
	The fair values of the Company's convertible notes were estimated using the (i) terms of the convertible notes; (ii) rights, preferences, privileges, and restrictions of the underlying security; (iii) time until any restriction(s) are released; (iv) fundamental financial and other characteristics of the Company; (v) trading characteristics of the underlying security (exchange, volume, price, and volatility); and (vi) precedent sale transactions. The fair values of the Company's non-recourse Sensipar notes, recombinant human parathyroid hormone [1-84] ("rhPTH 1-84")-secured debt and Regpara-secured debt were estimated using a discounted cash flow model. Within the hierarchy of fair value measurements, these are Level 3 fair values.

Financial_Instruments_Note_4

Financial Instruments - Note 4	6 Months Ended
	Jun. 30, 2014
Financial Instruments Disclosure	'
Financial Instruments	'
	(4) Financial Instruments
	Financial instruments that potentially subject the Company to concentrations of credit risk are accounts receivable and marketable investment securities. The majority of the Company's accounts receivable are payable by pharmaceutical companies and specialty pharmacies and collateral is generally not required from these companies. Substantially all of the Company's royalty revenues for the three and six months ended June 30, 2014 and 2013 were from three licensees and substantially all of the Company's accounts receivable balances at June 30, 2014 and December 31, 2013 were from three licensees. Substantially all of the Company's product sales revenues for the three and six months ended June 30, 2014 and 2013 and substantially all of the Company's trade accounts receivable balances at June 30, 2014 and December 31, 2013, were from six specialty pharmacies. The Company's portfolio of marketable investment securities is subject to concentration limits set within the Company's investment policy that help to mitigate its credit exposure.
	The following is a summary of the Company's marketable investment securities (in thousands):
					Gross		Gross
					unrealized		unrealized
			Amortized		holding		holding		Fair
			cost		gains		losses		value
	As of June 30, 2014:
	Debt securities:
	Corporate	$	102,216	$	35	$	-32	$	102,219
	Government agency		13,946		10		-		13,956
	Total marketable investment securites	$	116,162	$	45	$	-32	$	116,175
					Gross		Gross
					unrealized		unrealized
			Amortized		holding		holding		Fair
			cost		gains		losses		value
	As of December 31, 2013:
	Debt securities:
	Corporate	$	103,175	$	23	$	-60	$	103,138
	Government agency		26,110		22		-		26,132
	Total marketable investment securites	$	129,285	$	45	$	-60	$	129,270
	Marketable investment securities available for sale in an unrealized loss position as of June 30, 2014 and December 31, 2013 are summarized as follows (in thousands):
			Held for less than 12 months				Held for more than 12 months				Total
					Unrealized				Unrealized				Unrealized
			Fair value		losses		Fair value		losses		Fair value		losses
	As of June 30, 2014:
	Available for Sale:
	Debt securities:
	Corporate	$	62,672	$	32	$	-	$	-	$	62,672	$	32
	Government agency		-		-		-		-		-		-
		$	62,672	$	32	$	-	$	-	$	62,672	$	32
	As of December 31, 2013:
	Available for Sale:
	Debt securities:
	Corporate	$	74,407	$	56	$	5,732	$	4	$	80,139	$	60
	Government agency		-		-		-		-		-		-
		$	74,407	$	56	$	5,732	$	4	$	80,139	$	60
	Summary of Contractual Maturities
	Maturities of marketable investment securities are as follows at June 30, 2014 and December 31, 2013 (in thousands):
			As of June 30, 2014				As of December 31, 2013
			Amortized				Amortized
			cost		Fair value		cost		Fair value
	Due within one year	$	113,606	$	113,614	$	103,280	$	103,266
	Due after one year through five years		2,556		2,561		26,005		26,004
	Due after five years		-		-		-		-
	Total debt securities	$	116,162	$	116,175	$	129,285	$	129,270
	Impairments
	No impairment losses were recognized through earnings related to available for sale securities during the three and six months ended June 30, 2014 and 2013.
	Proceeds from Available for Sale Securities
	The proceeds from maturities and sales of available for sale securities and resulting realized gains and losses, were as follows (in thousands):
			For the Three Months				For the Six Months
			Ended June 30,				Ended June 30,
			2014		2013		2014		2013
	Proceeds from sales and maturities	$	40,097	$	18,650	$	77,959	$	46,657
	Realized gains		-		2		7		2
	Realized losses		-		-		-		-

Inventory_Note_5

Inventory - Note 5	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure	'
Inventory	'
	(5) Inventory
	Inventories are stated at the lower of cost or market. The Company began to capitalize inventory after the FDA approval of Gattex in December 2012. Inventory is as follows at June 30, 2014 and December 31, 2013 (in thousands):
			June 30,		December 31,
			2014		2013
	Raw materials	$	30,866	$	29,330
	Finished goods		1,814		705
	Total inventory	$	32,680	$	30,035

Longterm_Debt_Note_6

Long-term Debt - Note 6	6 Months Ended
	Jun. 30, 2014
Long-Term Debt Disclosure	'
Long-Term Debt	'
	(6) Long-term Debt
	The following table reflects the carrying value of the Company's long-term debt under various financing arrangements as of June 30, 2014 and December 31, 2013 (in thousands):
			June 30,		December 31,
			2014		2013
	Convertible notes	$	-	$	16,545
	Non-recourse debt		116,747		132,387
	Total debt		116,747		148,932
	Less current portion		9,270		25,297
	Total long-term debt	$	107,477	$	123,635
	(a) Convertible Notes
	On April 8, 2014, the holders of the 5.75% Convertible Notes ("5.75% Convertible Notes") converted the remaining outstanding notes at a conversion price of $5.44 per share. The Company issued 3.0 million shares pursuant to this conversion and retired the remaining $16.5 million of the outstanding 5.75% Convertible Notes.
	(b) Non-recourse Debt
	Sensipar- and Mimpara-Secured Non-recourse Debt
	As of June 30, 2014 and December 31, 2013, the outstanding principal balances on Sensipar- and Mimpara-secured non-recourse debt were $40.6 million and $54.4 million, respectively. The Sensipar- and Mimpara-secured debt is non-recourse to the Company and solely secured and serviced by Sensipar and Mimpara (cinacalcet HCl) royalties. The Company amended its agreement with Amgen effective September 30, 2011 whereby Amgen advanced $145.0 million of Sensipar and Mimpara royalties to the Company (the "Sensipar Notes"). The Sensipar Notes accrue interest at an annual rate of 9%, compounded quarterly and payable 45 days after the close of each quarter. The payment of the royalty advance and discount shall be satisfied solely by Amgen's withholding of royalties and except in the event of a breach of certain customary representations and warranties under the agreement, the Company will have no obligation to repay any unsettled amount. The Company further amended the agreement with Amgen effective June 29, 2012, limiting the royalty offset of the royalty advance up to $8.0 million per quarter with royalties in excess of $8.0 million paid to the Company for the respective quarter, thereby extending the royalty advance repayment period. After the payment of the royalty advance and a 9% per annum discount on the balance of the advance, Amgen will resume paying NPS Pharma all royalties earned through December 31, 2018. As of June 30, 2014 and December 31, 2013, the Company classified $7.1 million and $6.7 million, respectively, of the Sensipar Notes as current based on royalty payments accrued as of June 30, 2014 and December 31, 2013. Accrued interest on the Sensipar Notes was approximately $442,000 and $592,000 as of June 30, 2014 and December 31, 2013, respectively. The Company incurred debt issuance costs of $96,000, in September 2011, which are being amortized using the effective interest method. The effective interest rate on the Sensipar Notes, including debt issuance costs, is approximately 9%.
	rhPTH 1-84-Secured Non-recourse Debt
	As of June 30, 2014 and December 31, 2013, the outstanding principal balances on rhPTH 1-84-secured debt were $42.8 million, respectively. In July 2007, the Company entered into an agreement (the "2007 DRI Agreement") with DRI Capital ("DRI"), formerly Drug Royalty L.P.3, in which the Company sold to DRI its right to receive future royalty payments arising from sales of recombinant human parathyroid hormone 1-84 [rDNA origin] ("PTH") under its license agreement with Takeda (the "Takeda License Agreement"). Under the 2007 DRI Agreement, DRI paid the Company an up-front purchase price of $50.0 million. If and when DRI receives two and a half times the amount paid to the Company, the 2007 DRI Agreement will terminate and the remainder of the royalties, if any, will revert back to the Company. In connection with the Company's 2007 DRI Agreement, the Company granted DRI a security interest in its Takeda License Agreement for Preotact and certain of its patents and other intellectual property underlying the Takeda License Agreement. In the event of a default by NPS Pharma under the 2007 DRI Agreement, DRI would be entitled to enforce its security interest against the property described above.
	In December 2013, the Company entered into an amendment and restatement (the "Amendment and Restatement") to the 2007 DRI Agreement. Pursuant to the March 18, 2013 Termination and Transition Agreement between NPS Pharma and Takeda (the "Termination and Transition Agreement"), the Takeda License Agreement was terminated and NPS Pharma re-acquired exclusive rights worldwide, excluding Israel, to develop and commercialize rhPTH 1-84. Preotact is the brand name that Takeda had used to market rhPTH 1-84 for the treatment of osteoporosis in certain of its licensed territories. NPS Pharma is developing rhPTH 1-84 in the U.S. under the trade name Natpara® for the treatment of hypoparathyroidism. NPS Pharma filed a Biologic License Application ("BLA") for Natpara with the U.S. Food and Drug Administration (the "FDA") in October 2013.
	Pursuant to the Amendment and Restatement, (i) DRI has consented to the commercialization of rhPTH 1-84 by the Company, (ii) the terms of the 2007 DRI Agreement are tolled, and (iii) the parties' rights and obligations regarding PTH and related technology are governed by the Amendment and Restatement.
	The Company will be required to pay royalties in the mid-single digits to DRI based upon sales of rhPTH 1-84 by the Company and its licensees (if any) worldwide, excluding Israel. The Company has agreed to undertake certain efforts to commercialize rhPTH 1-84. If the Company does not submit a Marketing Authorization Application to the European Medicines Agency for rhPTH 1-84 in the European Union by an agreed upon date, DRI will have the right to revoke the consent granted in the Amendment and Restatement, reinstate the 2007 DRI Agreement, and either cause the Company to enter into a new license agreement with a third party with respect to rhPTH 1-84 on terms that are substantially similar and no more extensive (when taken as a whole) than the terms contained in the terminated Takeda License Agreement, or negotiate such an agreement on NPS Pharma's behalf.
	The Company's obligation to pay royalties to DRI under the Amendment and Restatement shall expire on a country-by-country basis upon the later of (i) the last to expire patent controlled by the Company with claims covering rhPTH 1-84 in such country or (ii) the expiration of any period of regulatory exclusivity applicable to rhPTH 1-84 in such country. The Company's obligation to pay royalties to DRI under the Amendment and Restatement shall terminate in its entirety once cumulative royalty payments made to DRI by Takeda and the Company total $125.0 million. As of June 30, 2014, $45.5 million in royalties had been paid to DRI.
	DRI continues to maintain a security interest in NPS Pharma patents that contain claims covering rhPTH 1-84 and certain other NPS Pharma intellectual property related to rhPTH 1-84. In the event of a default by NPS Pharma under the Amendment and Restatement, DRI would be entitled to enforce its security interest against NPS Pharma and such intellectual property.
	The Company determined the initial up-front purchase price is debt and is being amortized into earnings using the effective interest method over the estimated life. Accrued interest under the Amendment and Restatement was $3.1 million and $0 as of June 30, 2014 and December 31, 2013, respectively and is included as a component of other liabilities. The repayment of the remaining $42.8 million principal is secured solely by future royalty payments arising from sales of rhPTH 1-84 by the Company. The rhPTH 1-84-secured debt is non-recourse to the Company.
	REGPARA-Secured Non-recourse Debt
	As of June 30, 2014 and December 31, 2013, the outstanding principal balances on REGPARA-secured debt were $33.3 million and $35.2 million, respectively. In February 2010, the Company entered into an agreement with an affiliate of DRI (the "2010 DRI Agreement"), in which the Company sold to DRI its right to receive future royalty payments arising from sales of REGPARA® (cinacalcet HC1) under its license agreement with Kyowa Hakko Kirin. Under the 2010 DRI Agreement, DRI paid the Company an upfront purchase price of $38.4 million. If and when DRI receives two and a half times the amount paid to the Company, the 2010 DRI Agreement will terminate and the remainder of the royalties, if any, will revert back to the Company. In connection with the 2010 DRI Agreement, the Company granted DRI a security interest in its license agreement with Kyowa Hakko Kirin for REGPARA and certain of its patents and other intellectual property underlying that agreement. In the event of a default by NPS Pharma under the 2010 DRI Agreement, DRI would be entitled to enforce its security interest against NPS Pharma and the property described above. The Company classified the initial upfront purchase price as debt which is being amortized using the effective interest method over the estimated life of approximately 11 years. As of June 30, 2014 and December 31, 2013, the Company classified $2.2 million and $0, respectively, of the REGPARA-secured debt as current based on royalty payments accrued as of June 30, 2014 and December 31, 2013. Accrued interest under the 2010 DRI Agreement was $1.1 million as of June 30, 2014 and December 31, 2013, respectively. Through June 30, 2014, $31.9 million has been paid to DRI. The repayment of the remaining $33.3 million principal as of June 30, 2014, is secured solely by future royalty payments arising from sales of REGPARA by Kyowa Hakko Kirin. The effective interest rate under the 2010 DRI Agreement, including issuance costs, is approximately 16.0%. The REGPARA-secured debt is non-recourse to the Company.

Income_Taxes_Note_7

Income Taxes - Note 7	6 Months Ended
	Jun. 30, 2014
Income Taxes Disclosure	'
Income Taxes	'
	(7) Income Taxes
	The Company files income tax returns in various jurisdictions with varying statutes of limitations. The statute of limitations for income tax audits in the U.S. will commence upon utilization of net operating losses and will expire three years from the filing of the tax return. In August 2012, the IRS completed its examination of the Company's U.S. federal income tax returns for the year ended December 31, 2009.  In May 2013, the State of New Jersey completed its examination of the Company's New Jersey income tax returns through the year ended December 31, 2010. There were no adjustments as a result of these examinations.
	The Company accounts for penalties or interest related to uncertain tax positions as part of its provision for income taxes.  Due to the Company's net operating loss carryforwards, any adjustment related to a liability would not be expected to result in a cash tax liability. Accordingly, the Company has not accrued for penalties or interest for the U.S. (both federal and state) as of June 30, 2014 and December 31, 2013. Assuming the continued existence of a full valuation allowance on the Company's net deferred tax assets, future recognition of any of the Company's unrecognized tax benefits would not impact the effective tax rate.

Commitment_and_Contingencies_N

Commitment and Contingencies - Note 8	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure	'
Commitments and Contingencies	'
	(8) Commitments and Contingencies
	The Company has agreed to indemnify, under certain circumstances, certain manufacturers and service providers from and against any and all losses, claims, damages or liabilities arising from services provided by such manufacturers and service providers or from any use, including clinical trials, or sale by the Company or any Company agent of any product supplied by the manufacturers. The Company has entered into long-term agreements with various third-party contract manufacturers for the production and packaging of the active pharmaceutical ingredient and drug product. Under the terms of these various agreements, the Company may be required to purchase certain minimum quantities of product each year.

Stock_Options_Note_9

Stock Options - Note 9	6 Months Ended
	Jun. 30, 2014
Stock Option Plans	'
	(9) Stock Options
	The Company recognized $3.5 million and $7.6 million of compensation expense during the three and six months ended June 30, 2014, respectively, and $2.1 million and $5.1 million during the three and six months ended June 30, 2013, respectively, related to all stock based compensation. As of June 30, 2014, there was $34.5 million of total unrecognized compensation cost related to all unvested share-based compensation arrangements that is expected to be recognized over a weighted-average period of 2.90 years.
	During the year ended December 31, 2010, the Company's Board of Directors awarded a total of 1,130,700 performance condition options to certain of the Company's employees. Vesting of these options is subject to the Company achieving certain performance criteria established at the grant date and the individuals fulfilling a service condition (continued employment). As of June 30, 2014, the performance criteria of 884,590 of these options had been satisfied and have met the corresponding vesting criteria. The Company recognized $0 and $192,000 of compensation expense during the three and six months ended June 30, 2014, respectively, and $83,000 and $244,000 of compensation expense during the three and six months ended June 30, 2013, respectively, related to these options. The final performance criteria was not met and therefore the remaining 246,110 options have been forfeited.
	A summary of activity related to aggregate stock options under all plans is indicated in the following table (in thousands, except per share amounts):
		As of June 30, 2014
				Weighted	Weighted
		Number		average	average remaining		Aggregate
		of		exercise	contractual		intrinsic
		options		price	term		value
		(in thousands)			(in years)		(in thousands)
	Options outstanding at beginning
	of year	6,656	$	8.03
	Options granted	1,031		33.91
	Options exercised	727		8.37
	Options forfeited/expired	364		8.38
	Options outstanding at June 30, 2014	6,596		12.02	7.55	$	141,971
	Vested and expected to vest	6,211		11.55	7.46	$	136,305
	Options exercisable at June 30, 2014	3,179	$	6.47	6.29	$	84,503

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements - Note 10	6 Months Ended
	Jun. 30, 2014
Recent Accounting Pronouncements Disclosure	'
Recent Accounting Pronouncements	'
	(10) Recent Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position, results of operations or disclosures upon adoption.
	In May 2014, the FASB issued Accounting Standards Update ("ASU") No. 2014-09, "Revenue from Contracts with Customers," which requires entities to recognize revenue in the way it expects to be entitled for the transfer of promised goods or services to customers.  The ASU will replace most of the existing revenue recognition requirements in U.S. GAAP when it becomes effective.  This pronouncement is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted.  The Company is currently evaluating the effect that this pronouncement will have on its financial statements and related disclosures.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2014
Notes to Financial Statements	'
Principles of Consolidation	'
	The accompanying unaudited condensed consolidated financial statements included herein have been prepared by NPS Pharmaceuticals, Inc. (NPS Pharma or the Company) in accordance with the rules and regulations of the United States Securities and Exchange Commission (SEC). The condensed consolidated financial statements are comprised of the financial statements of NPS Pharma and its subsidiaries collectively referred to as the Company. In management's opinion, the interim financial data presented includes all adjustments (consisting solely of normal recurring items) necessary for fair presentation. All intercompany accounts and transactions have been eliminated. Certain information required by U.S. generally accepted accounting principles has been condensed or omitted in accordance with rules and regulations of the SEC. Operating results for the three or six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for any future period or for the year ending December 31, 2014.
	These condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and the notes thereto for the year ended December 31, 2013, included in NPS Pharma's 2013 Annual Report on Form 10-K filed with the SEC.
Use of Estimates	'
	The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions relating to reporting of the assets and liabilities and the disclosure of contingent assets and liabilities to prepare these condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period in conformity with U.S. generally accepted accounting principles. Actual results could differ from these estimates.
Subsequent Events	'
	The Company has evaluated all events and transactions since June 30, 2014. The Company did not have any material recognized or non-recognized subsequent events.
Income (Loss) per Common Share	'
	Basic net income (loss) per common share is the amount of income (loss) for the period divided by the weighted average shares of common stock outstanding during the reporting period. Diluted income (loss) per common share is the amount of income (loss) for the period plus interest expense on convertible debt divided by the sum of weighted average shares of common stock outstanding during the reporting period and weighted average shares that would have been outstanding assuming the issuance of common shares for all dilutive potential common shares.
Inventory	'
	Inventories are stated at the lower of cost or market.
Fair Value of Financial Instruments	'
	The Company's financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows:
	Level 1- Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
	Level 2- Inputs are other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
	Level 3- Inputs are unobservable and reflect the Company's assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.
	The fair values of the Company's convertible notes were estimated using the (i) terms of the convertible notes; (ii) rights, preferences, privileges, and restrictions of the underlying security; (iii) time until any restriction(s) are released; (iv) fundamental financial and other characteristics of the Company; (v) trading characteristics of the underlying security (exchange, volume, price, and volatility); and (vi) precedent sale transactions. The fair values of the Company's non-recourse Sensipar notes, recombinant human parathyroid hormone [1-84] ("rhPTH 1-84")-secured debt and Regpara-secured debt were estimated using a discounted cash flow model. Within the hierarchy of fair value measurements, these are Level 3 fair values.
Income Taxes	'
	The Company accounts for penalties or interest related to uncertain tax positions as part of its provision for income taxes.  Due to the Company's net operating loss carryforwards, any adjustment related to a liability would not be expected to result in a cash tax liability. Accordingly, the Company has not accrued for penalties or interest for the U.S. (both federal and state) as of June 30, 2014 and December 31, 2013. Assuming the continued existence of a full valuation allowance on the Company's net deferred tax assets, future recognition of any of the Company's unrecognized tax benefits would not impact the effective tax rate.

Income_Loss_Per_Common_Share_T

Income (Loss) Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2014
Income Loss Per Common Share Tables	'
Income (Loss) Per Common Share (Tables)	'
	The following table sets forth the components of basic and diluted income per common share for the three months ended June 30, 2014 due to net income in the three month period (in thousands, except per share data):
		Three Months
		Ended
			30-Jun-14
	EPS Numerator — Basic:
	Net income	$	1,992
	EPS Denominator — Basic:
	Weighted-average number of shares of common
	stock outstanding		106,807
	EPS Numerator — Diluted:
	Net income	$	1,992
	EPS Denominator — Diluted:
	Weighted-average number of shares of common
	stock outstanding		106,807
	Effect of dilutive securities:
	Stock options and awards		3,696
	Dilutive potential common shares		3,696
	Weighted-average common shares and dilutive
	potential common shares		110,503
	Basic net income per common share	$	0.02
	Diluted net income per common share	$	0.02

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2014
Notes to Financial Statements	'
Fair Value Measurement (Tables)	'
	In accordance with the fair value hierarchy described above, the following table shows the fair value of the Company's financial assets (only marketable investment securities) that are required to be measured at fair value as of June 30, 2014 and December 31, 2013 (in thousands):
	As of June 30, 2014:		Level 1			Level 2			Level 3			Total
	Certificate of deposits	$	-		$	13,602		$	-		$	13,602
	Corporate		-			88,615			-			88,615
	Government agencies		-			14,458			-			14,458
	Money market funds		37,903			-			-			37,903
	Total assets at fair value	$	37,903		$	116,675		$	-		$	154,578
	As of December 31, 2013:		Level 1			Level 2			Level 3			Total
	Certificate of deposits	$	-		$	13,020		$	-		$	13,020
	Corporate		-			91,887			-			91,887
	Government agencies		-			27,131			-			27,131
	Money market funds		23,043			-			-			23,043
	Total assets at fair value	$	23,043		$	132,038		$	-		$	155,081
Fair and Carrying Value of Debt Instruments	'
	The fair and carrying value of our debt instruments are detailed as follows (in thousands):
					As of June 30, 2014						As of December 31, 2013
					Fair			Carrying			Fair			Carrying
					Value			Value			Value			Value
	5.75% Convertible Notes*			$	-		$	-		$	92,338		$	16,545
	Sensipar Notes				40,550			40,616			54,097			54,395
	rhPTH 1-84-Secured Debt				53,415			42,790			50,058			42,790
	Regpara-Secured Debt				36,376			33,341			37,348			35,202
	Total			$	130,341		$	116,747		$	233,841		$	148,932
	* See Note 6

Financial_Instruments_Tables

Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2014
Notes to Financial Statements	'
Marketable investment securities	'
	The following is a summary of the Company's marketable investment securities (in thousands):
					Gross		Gross
					unrealized		unrealized
			Amortized		holding		holding		Fair
			cost		gains		losses		value
	As of June 30, 2014:
	Debt securities:
	Corporate	$	102,216	$	35	$	-32	$	102,219
	Government agency		13,946		10		-		13,956
	Total marketable investment securites	$	116,162	$	45	$	-32	$	116,175
					Gross		Gross
					unrealized		unrealized
			Amortized		holding		holding		Fair
			cost		gains		losses		value
	As of December 31, 2013:
	Debt securities:
	Corporate	$	103,175	$	23	$	-60	$	103,138
	Government agency		26,110		22		-		26,132
	Total marketable investment securites	$	129,285	$	45	$	-60	$	129,270
Marketable investment securities available for sale in an unrealized loss position	'
	Marketable investment securities available for sale in an unrealized loss position as of June 30, 2014 and December 31, 2013 are summarized as follows (in thousands):
			Held for less than 12 months				Held for more than 12 months				Total
					Unrealized				Unrealized				Unrealized
			Fair value		losses		Fair value		losses		Fair value		losses
	As of June 30, 2014:
	Available for Sale:
	Debt securities:
	Corporate	$	62,672	$	32	$	-	$	-	$	62,672	$	32
	Government agency		-		-		-		-		-		-
		$	62,672	$	32	$	-	$	-	$	62,672	$	32
	As of December 31, 2013:
	Available for Sale:
	Debt securities:
	Corporate	$	74,407	$	56	$	5,732	$	4	$	80,139	$	60
	Government agency		-		-		-		-		-		-
		$	74,407	$	56	$	5,732	$	4	$	80,139	$	60
Maturities of marketable investment securities	'
	Summary of Contractual Maturities
	Maturities of marketable investment securities are as follows at June 30, 2014 and December 31, 2013 (in thousands):
			As of June 30, 2014				As of December 31, 2013
			Amortized				Amortized
			cost		Fair value		cost		Fair value
	Due within one year	$	113,606	$	113,614	$	103,280	$	103,266
	Due after one year through five years		2,556		2,561		26,005		26,004
	Due after five years		-		-		-		-
	Total debt securities	$	116,162	$	116,175	$	129,285	$	129,270
Proceeds from maturities and sales of available for sale securities and resulting gain and losses	'
	The proceeds from maturities and sales of available for sale securities and resulting realized gains and losses, were as follows (in thousands):
			For the Three Months				For the Six Months
			Ended June 30,				Ended June 30,
			2014		2013		2014		2013
	Proceeds from sales and maturities	$	40,097	$	18,650	$	77,959	$	46,657
	Realized gains		-		2		7		2
	Realized losses		-		-		-		-

Inventory_Tables

Inventory (Tables)	6 Months Ended
	Jun. 30, 2014
Inventory Tables	'
Inventory	'
	Inventory is as follows at June 30, 2014 and December 31, 2013 (in thousands):
			June 30,		December 31,
			2014		2013
	Raw materials	$	30,866	$	29,330
	Finished goods		1,814		705
	Total inventory	$	32,680	$	30,035

Longterm_Debt_Tables

Long-term Debt (Tables)	6 Months Ended
	Jun. 30, 2014
Notes to Financial Statements	'
Long-term Debt (Tables)	'
	The following table reflects the carrying value of the Company's long-term debt under various financing arrangements as of June 30, 2014 and December 31, 2013 (in thousands):
			June 30,		December 31,
			2014		2013
	Convertible notes	$	-	$	16,545
	Non-recourse debt		116,747		132,387
	Total debt		116,747		148,932
	Less current portion		9,270		25,297
	Total long-term debt	$	107,477	$	123,635

Stock_Options_Tables

Stock Options (Tables)	6 Months Ended
	Jun. 30, 2014
Stock Options Tables	'
Disclosure Of Share-Based Compensation Arrangements By Share-Based Payment Award	'
	A summary of activity related to aggregate stock options under all plans is indicated in the following table (in thousands, except per share amounts):
		As of June 30, 2014
				Weighted	Weighted
		Number		average	average remaining		Aggregate
		of		exercise	contractual		intrinsic
		options		price	term		value
		(in thousands)			(in years)		(in thousands)
	Options outstanding at beginning
	of year	6,656	$	8.03
	Options granted	1,031		33.91
	Options exercised	727		8.37
	Options forfeited/expired	364		8.38
	Options outstanding at June 30, 2014	6,596		12.02	7.55	$	141,971
	Vested and expected to vest	6,211		11.55	7.46	$	136,305
	Options exercisable at June 30, 2014	3,179	$	6.47	6.29	$	84,503

Income_Loss_Per_Common_Share_D

Income (Loss) Per Common Share (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
EPS Numerator - Basic:	'	'	'	'
Net income	$1,992	($12,389)	($4,584)	($20,185)
EPS Denominator - Basic:	'	'	'	'
Weighted-average number of shares of common stock outstanding	106,807	97,321	105,218	92,886
EPS Numerator - Diluted:	'	'	'	'
Net income	$1,992	($12,389)	($4,584)	($20,185)
EPS Denominator - Diluted:	'	'	'	'
Weighted-average number of shares of common stock outstanding	106,807	97,321	105,218	92,886
Stock options and awards	3,696	'	'	'
Dilutive potential common shares	3,696	'	'	'
Weighted-average common shares and dilutive potential common shares	110,503	97,321	105,218	92,886
Basic net income per common share	$0.02	($0.13)	($0.04)	($0.22)
Diluted net income per common share	$0.02	($0.13)	($0.04)	($0.22)

Income_Loss_Per_Share_Narrativ

Income (Loss) Per Share (Narrative) (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Anti-dilutive shares	1,400,000	6,300,000	6,500,000	8,100,000
Convertible Notes Payable	'	'	'	'
Anti-dilutive shares	267,000	3,000,000	1,600,000	3,000,000
Stock Options Restricted Stock And Restricted Stock Units	'	'	'	'
Anti-dilutive shares	1,100,000	3,300,000	4,800,000	5,100,000

Fair_Value_Measurement_Securit

Fair Value Measurement (Securities) (Details 1) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Certificates of deposit	$13,602	$13,020
Corporate	88,615	91,887
Government agencies	14,458	27,131
Money market funds	37,903	23,043
Total assets at fair value	154,578	155,081
Level 1	'	'
Certificates of deposit	0	0
Corporate	0	0
Government agencies	0	0
Money market funds	37,903	23,043
Total assets at fair value	37,903	23,043
Level 2	'	'
Certificates of deposit	13,602	13,020
Corporate	88,615	91,887
Government agencies	14,458	27,131
Money market funds	0	0
Total assets at fair value	116,675	132,038
Level 3	'	'
Certificates of deposit	0	0
Corporate	0	0
Government agencies	0	0
Money market funds	0	0
Total assets at fair value	$0	$0

Fair_Value_Measurement_Debt_In

Fair Value Measurement (Debt Instruments) (Details 2) (USD $)	Jun. 30, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Debt instruments, fair value	$130,341		$233,841
Debt instruments, carrying value	116,747		148,932
Convertible Notes	'		'
Debt instruments, fair value	0	[1]	92,338	[1]
Debt instruments, carrying value	0	[1]	16,545	[1]
Sensipar Notes	'		'
Debt instruments, fair value	40,550		54,097
Debt instruments, carrying value	40,616		54,395
rhPTH 1-84-Secured Debt	'		'
Debt instruments, fair value	53,415		50,058
Debt instruments, carrying value	42,790		42,790
Regpara-Secured Debt	'		'
Debt instruments, fair value	36,376		37,348
Debt instruments, carrying value	$33,341		$35,202
[1]	See Note 6

Fair_Value_Measurement_Liabili

Fair Value Measurement (Liabilities Narrative) (Details 3) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Fair Value Measurement Liabilities Narrative Details 3	'	'
Brigham Women's Hospital royalty liability, fair value	$3.50	$4.30
Brigham Women's Hospital royalty liability, carrying value	$4.60	$5.60

Financial_Instruments_Fair_Val

Financial Instruments (Fair Value Of Investments) (Details 1) (USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Amortized cost	$116,162	$129,285
Gross unrealized holding gains	45	45
Gross unrealized holding losses	-32	-60
Fair value	154,578	155,081
Corporate	'	'
Amortized cost	102,216	103,175
Gross unrealized holding gains	35	23
Gross unrealized holding losses	-32	-60
Fair value	102,219	103,138
Government agency	'	'
Amortized cost	13,946	26,110
Gross unrealized holding gains	10	22
Gross unrealized holding losses	0	0
Fair value	$13,956	$26,132

Financial_Instruments_Fair_Val1

Financial Instruments (Fair Value Of Investments) (Details 2) (USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Marketable investment securities available for sale in an unrealized loss position	'	'
In Loss Position for Less Than 12 Months, Fair Value	$62,672	$74,407
In Loss Position for Less Than 12 Months, Gross Unrealized Losses	32	56
In Loss Position for More Than 12 Months, Fair Value	0	5,732
In Loss Position for More Than 12 Months, Gross Unrealized Losses	0	4
Total, Fair Value	62,672	80,139
Total, Gross Unrealized Losses	32	60
Corporate	'	'
Marketable investment securities available for sale in an unrealized loss position	'	'
In Loss Position for Less Than 12 Months, Fair Value	62,672	74,407
In Loss Position for Less Than 12 Months, Gross Unrealized Losses	32	56
In Loss Position for More Than 12 Months, Fair Value	0	5,732
In Loss Position for More Than 12 Months, Gross Unrealized Losses	0	4
Total, Fair Value	62,672	80,139
Total, Gross Unrealized Losses	32	60
Government agency	'	'
Marketable investment securities available for sale in an unrealized loss position	'	'
In Loss Position for Less Than 12 Months, Fair Value	0	0
In Loss Position for Less Than 12 Months, Gross Unrealized Losses	0	0
In Loss Position for More Than 12 Months, Fair Value	0	0
In Loss Position for More Than 12 Months, Gross Unrealized Losses	0	0
Total, Fair Value	0	0
Total, Gross Unrealized Losses	$0	$0

Financial_Instruments_Contract

Financial Instruments (Contractual Maturities) (Details 3) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Financial Instruments Contractual Maturities Details 3	'	'
Due within one year, amortized cost	$113,606	$103,280
Due after one year through five years, amortized cost	2,556	26,005
Due after five years through ten years, amortized cost	0	0
Due within one year, fair value	113,614	103,266
Due after one year through five years, fair value	2,561	26,004
Due after five years through ten years, fair value	0	0
Total debt securities, amortized cost	116,162	129,285
Total debt securities, fair value	$116,175	$129,270

Financial_Instruments_Proceeds

Financial Instruments (Proceeds) (Details 4) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Financial Instruments Proceeds Details 4	'	'	'	'
Proceeds from sales and maturities	$40,097	$18,650	$77,959	$46,657
Realized gains	0	2	7	2
Realized losses	$0	$0	$0	$0

Financial_Instruments_Narrativ

Financial Instruments (Narrative) (Details 5) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Financial Instruments Narrative Details 5	'	'
Impairment losses	$0	$0

Inventory_Details

Inventory (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Details	'	'
Raw materials	$30,866	$29,330
Finished goods	1,814	705
Total inventory	$32,680	$30,035

Longterm_Debt_Details_1

Long-term Debt (Details 1) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Long-Term Debt Details 1	'	'
Convertible notes	$0	$16,545
Non-recourse debt	116,747	132,387
Total debt	116,747	148,932
Less current portion	9,270	25,297
Total long-term debt	$107,477	$123,635

Longterm_Debt_Convertible_Note

Long-term Debt Convertible Notes (Narrative) (Details) (USD $)	1 Months Ended
In Millions, except Share data, unless otherwise specified	Apr. 30, 2014
Long-Term Debt Convertible Notes Narrative Details	'
Conversion of 5.75% convertible notes, shares	3,041,451
Stock Issued During Period, Per Share, New Issues	$5.44
Conversion of 5.75% convertible notes	$16.50

Longterm_Debt_Narrative_Detail

Long-term Debt (Narrative) (Details 2) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Interest rate	5.75%	'
Sensipar and Mimpara-Secured Non-recourse Debt Sensipar Notes	'	'
Debt outstanding	$40.60	$54.40
Debt classified as current	7.1	6.7
Month and year of issue	30-Sep-11	'
Month and year of amendment	'June 2012	'
Interest rate	'	9.00%
Effective interest rate	'	9.00%
Debt amount originally issued	'	145
Net proceeds upon original issuance	'	144.9
Interest accrued	0.4	0.6
Quarterly limit of royalty offset of the royalty advance	8	'
rhPTH 1-84-Secured Non-recourse Debt	'	'
Debt outstanding	42.8	42.8
Month and year of issue	31-Jul-07	'
Month and year of amendment	'2013-12-31	'
Debt amount originally issued	'	50
Net proceeds upon original issuance	'	50
Interest accrued	3.1	0
Interest and principal paid to date	'	45.5
REGPARA-Secured Non-recourse Debt	'	'
Debt outstanding	33.3	35.2
Debt classified as current	2.2	0
Month and year of issue	28-Feb-10	'
Interest rate	'	16.00%
Effective interest rate	'	16.00%
Debt amount originally issued	'	38.4
Net proceeds upon original issuance	'	38.4
Deferred debt issuance costs amortization period, in years	'10 years	'
Interest accrued	1.1	1.1
Interest and principal paid to date	'	$31.90

Income_Taxes_Narrative_of_Expe

Income Taxes (Narrative of Expense) (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Income Taxes Narrative Of Expense Details	'	'
Accrued penalties and interest	$0	$0
Other Information Pertaining to Income Taxes	'	'
	The Company files income tax returns in various jurisdictions with varying statutes of limitations. The statute of limitations for income tax audits in the U.S. will commence upon utilization of net operating losses and will expire three years from the filing of the tax return. In August 2012, the IRS completed its examination of the Company's U.S. federal income tax returns for the year ended December 31, 2009.  In May 2013, the State of New Jersey completed its examination of the Company's New Jersey income tax returns through the year ended December 31, 2010. There were no adjustments as a result of these examinations.

Stock_Options_Compensation_Exp

Stock Options (Compensation Expense Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Stock Options Compensation Expense Narrative Details	'	'	'	'
Compensation expense on share-based awards	$3.50	$2.10	$7.60	$5.10
Unrecognized compensation cost	$34.50	'	$34.50	'
Weighted average period over which unrecognized compensation is expected to be recognized, in years	'	'	'2 years 329 days	'

Stock_Options_Performance_Cond

Stock Options (Performance Conditions Options Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
			Performance Condition Options	Performance Condition Options
Description of award	'	'	'	'
			During the year ended December 31, 2010, the Company's Board of Directors awarded a total of 1,130,700 performance condition options to certain of the Company's employees. Vesting of these options is subject to the Company achieving certain performance criteria established at the grant date and the individuals fulfilling a service condition (continued employment). As of June 30, 2014, the performance criteria of 884,590 of these options had been satisfied and have met the corresponding vesting criteria. The Company recognized $0 and $192,000 of compensation expense during the three and six months ended June 30, 2014, respectively, and $83,000 and $244,000 of compensation expense during the three and six months ended June 30, 2013, respectively, related to these options. The final performance criteria was not met and therefore the remaining 246,110 options have been forfeited.
Share-based Compensation Expense	$0	$83,000	$192,000	$244,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	'	'	1,130,700	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	'	'	884,590	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares	'	'	246,110	'

Stock_Options_Aggregate_Activi

Stock Options (Aggregate Activity Under Stock Option Plans) (Details) (USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014
Stock Options Aggregate Activity Under Stock Option Plans Details	'
Options outstanding at beginning of year	6,656,000
Options granted	1,031,000
Options exercised	727,000
Options forfeited/expired	364,000
Options outstanding at June 30, 2014	6,596,000
Weighted-average exercise price of options outstanding, beginning of year	$8.03
Weighted-average exercise price of options granted during period	$33.91
Weighted-average exercise price of options exercised during the period	$8.37
Weighted-average exercise price of options forfeited/expired during the period	$8.38
Weighted-average exercise price of options outstanding, at June 30, 2014	$12.02
Weighted-average remaining contractual term of options outstanding, at June 30, 2014	'7 years 201 days
Aggregate intrinsic value of options outstanding, at June 30, 2014	$141,971
Options Vested and Expected to Vest, Number of Shares	6,211,000
Options Vested and Expected to Vest, Weighted-Average Exercise Price Per Share	$11.55
Options Vested and Expected to Vest, Weighted-Average Remaining Contractual Term	'7 years 168 days
Options Vested and Expected to Vest, Aggregate Intrinsic Value	136,305
Options Exercisable, Number of Shares	3,179,000
Options Exercisable, Weighted-Average Exercise Price Per Share	$6.47
Options Exercisable, Weighted-Average Remaining Contractual Term	'6 years 106 days
Options Exercisable, Aggregate Intrinsic Value	$84,503